Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study
The intravenous formulation for supplementing iron currently available in Japan requires frequent administration. In contrast, ferric carboxymaltose (FCM) can improve iron-deficiency anemia (IDA) with only a small number of administrations; however, its efficacy and safety have not been established in Japanese patients. In this randomized, open-label study, we verified the noninferiority of FCM to saccharated ferric oxide (SFO) in Japanese patients with IDA due to hypermenorrhea, with the mean change from baseline to the highest observed hemoglobin level as the primary endpoint. Two hundred and thirty-eight eligible subjects (119 in FCM group, 119 in SFO group) were administered the investigational medicinal product and included in the analysis. The adjusted mean change from baseline to the highest observed hemoglobin level (95% CI) was 3.90 g/dL (3.77, 4.04) in the FCM group and 4.05 g/dL (3.92, 4.19) in the SFO group, and the difference between the groups (95% CI) was − 0.15 g/dL (− 0.35, 0.04). The noninferiority of FCM was verified. Incidence of adverse events was < 60% in both groups, and no significant difference was observed between the treatment groups. These results indicate that FCM can be a new, well-tolerated, and rapid treatment option for Japanese patients with IDA.
Ferric carboxymaltose (FCM) Iron-deficiency anemia (IDA) Hypermenorrhea Japan Intravenous iron
This is a preview of subscription content, log in to check access.
The authors are grateful to the patients and their families for their contributions. Funding was provided by Zeria Pharmaceutical Co., Ltd.
Compliance with ethical standards
Conflict of interest
The present study was performed as a Phase III study funded by Zeria Pharmaceutical Co., Ltd. Hanashi, Hirai and Ota received research funding from Zeria Pharmaceutical Co., Ltd. Ikuta received personal fees as medical specialist from Zeria Pharmaceutical Co., Ltd. Momoeda received personal fees as coordinating investigator from Zeria Pharmaceutical Co., Ltd. Matsuyama received personal fees as medical statistics advisor from Statcom Company Limited. Shimura and Terauchi are employees of Zeria Pharmaceutical Co., Ltd.
Supplemental Fig. 1 Proportion of subjects achieving increase in hemoglobin ≥2 g/dL based on the change in hemoglobin (Proportion±95% CI) (FAS). Proportion of subjects achieving a hemoglobin increase ≥2.0 g/dL at each evaluation point. Filled circle: ferric carboxymaltose, open circle: saccharated ferric oxide (JPEG 69 KB)
Supplemental Fig. 2 Proportion of subjects with a normalized hemoglobin (Proportion±95% CI) (FAS). Proportion of subjects achieving a hemoglobin≧12.0 g/dL at each evaluation point. Filled circle: ferric carboxymaltose, open circle: saccharated ferric oxide (JPEG 69 KB)
World Health Organization. Iron deficiency anemia—assessment, prevention, and control. A guide for program managers. Report No.: Document WHO/NHD/01.3. 2001.Google Scholar
Adamson JW. Iron deficiency and other hypoproliferative anemias. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison’s principles of internal medicine. 18th ed. New York: McGraw-Hill Companies; 2013. pp. 844–51.Google Scholar
Marret H, Fauconnier A, Chabbert-Buffet N, Cravello L, Golfier F, Gondry J, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol. 2010;152:133–7.CrossRefGoogle Scholar
Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung. 2010;60:345–53.Google Scholar
Beshara S, Sörensen J, Lubberink M, Tolmachev V, Långström B, Antoni G, et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol. 2003;120:853–9.CrossRefGoogle Scholar
Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018;107:16–30.CrossRefGoogle Scholar
Ikuta K, Shimura A, Terauchi M, Yoshii K, Kawabata Y. Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia. Int J Hematol. 2018;107:519–27.CrossRefGoogle Scholar
Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49:2719–28.CrossRefGoogle Scholar
Seid MH, Butcher AD, Chatwani A. Ferric carboxymaltose as treatment in women with iron-deficiency anemia. Anemia. 2017;2017:9642027.CrossRefGoogle Scholar
Suzuki T, Tomonaga M, Miyazaki Y, Nakao S, Ohyashiki K, Matsumura I, et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol. 2008;88:30–5.CrossRefGoogle Scholar
Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124:873–81.CrossRefGoogle Scholar
Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, et al. 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Renal Replace Ther. 2017;3:36.CrossRefGoogle Scholar